[1] Eiseman B,Silen W,Bascom G S,et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery,1958,44（5）:854-859.
[2] Rossen N G,Macdonald J K,de Vries E M,et al. Fecal microbiota transplantation as novel therapy in gastroenterology:A systematic review. World J Gastroenterol,2015,21（17）:5359-5371.
[3] Lonardo A,Bellentani S,Argo CK,et al. Epidemiological modifiers of non-alcoholic fatty liver disease:Focus on high-risk groups. Dig Liver Dis,2015,47（12）:997-1006.
[4] 周永健,聂玉强,李瑜元,等. 广东省成人代谢综合征与非酒精性脂肪肝患病的关系. 胃肠病学和肝病学杂志,2008,17（8）:647-649.
[5] Ampuero J,Ranchal I,Gallego-Duran R,et al. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. J Gastroenterol Hepatol,2016,31（9）:1611-1618.
[6] Rinella ME. Nonalcoholic fatty liver disease:a systematic review. JAMA,2015,313（22）:2263-2273.
[7] Sepideh A,Karim P,Hossein A,et al. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease:A double-blind randomized clinical trial. J Am Coll Nutr,2016,35（6）:500-505.
[8] Le Roy T,Llopis M,Lepage P,et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut,2013,62（12）:1787-1794.
[9] Graoph H. Structure,function and diversity of the healthy human microbiome. Nature,2012,486（7402）:207-214.
[10] Ridaura VK,Faith JJ,Rey FE et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science,2013,341（6150）:1241214.
[11] Turnbaugh PJ,Ley RE,Mahowald MA,et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature,2006,444（7122）:1027-1031.
[12] Zhou D,Pan Q,Shen F,et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep,2017,7（1）:1529.
[13] Michail S,Lin M,Frey MR,et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol,2014,91（2）:1-9.
[14] Spencer MD,Hamp TJ,Reid RW,et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology,2011,140（3）:976-986.
[15] Zhu L,Baker SS,Gill C,et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis（NASH） patients:a connection between endogenous alcohol and NASH. Hepatology,2013,57（2）:601-609.
[16] Wong VW,Tse CH,Lam TT,et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis-a longitudinal study. PLoS One,2013,8（4）:e62885.
[17] Miele L,Valenza V,La Torre G,et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology,2009,49（6）:1877-1887.
[18] Gabele E,Dostert K,Hofmann C,et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol,2011,55（6）:1391-1399.
[19] 蔡冰,周永健,李瑜元,等. 脂联素基因启动子区甲基化状态对大鼠实验性非酒精性脂肪性肝病的影响. 临床和实验医学杂志,2015,15（3）:169-173.
[20] Maslowski KM,Vieira AT,Ng A,et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature,2009,461（7268）:1282-1286.
[21] Volynets V,Kuper MA,Strahl S,et al. Nutrition,intestinal permeability,and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease （NAFLD）. Dig Dis Sci,2012,57（7）:1932-1941.
[22] Jiang C,Xie C,Lyu Y,et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Communicat,2015,6:10166.
[23] Houten SM,Volle DH,Cummins CL,et al. In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue. Mol Endocrinol,2007,21（6）:1312-1323.
[24] Wei Y,Gong J,Zhu W,et al. Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora. BMC Microbiol,2016,16（1）:255.
[25] Kelly CR,Kahn S,Kashyap P,et al. Update on fecal microbiota transplantation 2015:Indications,methodologies,mechanisms,and Outlook. Gastroenterology,2015,149（1）:223-237.
[26] Rossen NG. Fecal microbiota transplantation as novel therapy in gastroenterology:A systematic review. World J Gastroenterol,2015,21（17）:5359.
[27] Rubin DT. Fecal microbiota transplantation for the treatment of inflammatory bowel disease. Gastroenterol Hepatol （NY）,2015,11（9）:618-620.
[28] Wang S,Xu M,Wang W,et al. Systematic review:Adverse events of fecal microbiota transplantation. PLoS One,2016,11（8）:e161174. |
